1. Home
  2. EOI vs NUVB Comparison

EOI vs NUVB Comparison

Compare EOI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest

EOI

Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest

HOLD

Current Price

$19.20

Market Cap

742.1M

Sector

Finance

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.49

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EOI
NUVB
Founded
N/A
2018
Country
United States
United States
Employees
N/A
291
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
742.1M
1.6B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
EOI
NUVB
Price
$19.20
$4.49
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$11.38
AVG Volume (30 Days)
72.0K
3.4M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$190.15
Revenue Next Year
N/A
$62.54
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.55
$1.57
52 Week High
$21.58
$9.75

Technical Indicators

Market Signals
Indicator
EOI
NUVB
Relative Strength Index (RSI) 48.29 45.74
Support Level $18.04 $4.06
Resistance Level $20.90 $5.55
Average True Range (ATR) 0.35 0.21
MACD 0.09 0.08
Stochastic Oscillator 74.10 72.12

Price Performance

Historical Comparison
EOI
NUVB

About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest

Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: